These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25885288)

  • 21. The additional value of ONEST (Observers Needed to Evaluate Subjective Tests) in assessing reproducibility of oestrogen receptor, progesterone receptor, and Ki67 classification in breast cancer.
    Cserni B; Bori R; Csörgő E; Oláh-Németh O; Pancsa T; Sejben A; Sejben I; Vörös A; Zombori T; Nyári T; Cserni G
    Virchows Arch; 2021 Dec; 479(6):1101-1109. PubMed ID: 34415429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ki67 and CD31 Differential Expression in Cutaneous T-Cell Lymphoma and Its Mimickers: Association with Clinicopathological Criteria and Disease Advancement.
    Zohdy M; Abd El Hafez A; Abd Allah MYY; Bessar H; Refat S
    Clin Cosmet Investig Dermatol; 2020; 13():431-442. PubMed ID: 32606882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer.
    Maranta AF; Broder S; Fritzsche C; Knauer M; Thürlimann B; Jochum W; Ruhstaller T
    Breast; 2020 Jun; 51():120-126. PubMed ID: 32302928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Vissio E; Metovic J; Osella-Abate S; Bertero L; Migliaretti G; Borella F; Benedetto C; Sapino A; Cassoni P; Castellano I
    Br J Cancer; 2020 Feb; 122(3):382-387. PubMed ID: 31780778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
    Stevanovic L; Choschzick M; Moskovszky L; Varga Z
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort.
    Varga Z; Li Q; Jochum W; Perriard U; Rau T; Tille JC; Hawle H; Klingbiel D; Thuerlimann B; Ruhstaller T
    Sci Rep; 2019 Sep; 9(1):13534. PubMed ID: 31537812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of monoclonal antibodies in pathological diagnostics].
    Förster S; Tannapfel A
    Internist (Berl); 2019 Oct; 60(10):1021-1031. PubMed ID: 31486857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Update of the German S3 breast cancer guideline : What is new for pathologists?].
    Lebeau A; Denkert C; Sinn P; Schmidt M; Wöckel A
    Pathologe; 2019 Mar; 40(2):185-198. PubMed ID: 30847505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.
    van Steenhoven JEC; Kuijer A; van Diest PJ; van Gorp JM; Straver M; Elias SG; Wesseling J; Rutgers E; Timmer-Bonte JNH; Nieboer P; Smilde TJ; Imholz A; Blanken CFJM; Siesling S; van Dalen T
    Genes (Basel); 2018 May; 9(5):. PubMed ID: 29772837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
    Varga Z; Lebeau A; Bu H; Hartmann A; Penault-Llorca F; Guerini-Rocco E; Schraml P; Symmans F; Stoehr R; Teng X; Turzynski A; von Wasielewski R; Gürtler C; Laible M; Schlombs K; Joensuu H; Keller T; Sinn P; Sahin U; Bartlett J; Viale G
    Breast Cancer Res; 2017 May; 19(1):55. PubMed ID: 28490348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer.
    Ács B; Madaras L; Kovács KA; Micsik T; Tőkés AM; Győrffy B; Kulka J; Szász AM
    Pathol Oncol Res; 2018 Jan; 24(1):115-127. PubMed ID: 28401450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
    Jang MH; Kim HJ; Chung YR; Lee Y; Park SY
    PLoS One; 2017; 12(2):e0172031. PubMed ID: 28187177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
    Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
    PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.
    Varga Z; Cassoly E; Li Q; Oehlschlegel C; Tapia C; Lehr HA; Klingbiel D; Thürlimann B; Ruhstaller T
    PLoS One; 2015; 10(4):e0123435. PubMed ID: 25885288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting.
    Harvey J; Thomas C; Wood B; Hardie M; Dessauvagie B; Combrinck M; Frost FA; Sterrett G
    Pathology; 2015 Jan; 47(1):13-20. PubMed ID: 25474507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.
    Vörös A; Csörgő E; Nyári T; Cserni G
    Pathobiology; 2013; 80(3):111-8. PubMed ID: 23258384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment.
    Ayad E; Soliman A; Anis SE; Salem AB; Hu P; Dong Y
    Diagn Pathol; 2018 Aug; 13(1):63. PubMed ID: 30153851
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.